← back to evidence hierarchy
evidence card · routine_inpatient_stress_test_low_value

Routine inpatient stress testing in low-risk hospitalized patients is low-value care

Established consensus
H4 ▲ supports stakes moderate
1 post scored · across 1 account · 4 sources

Summary

Multiple professional society Choosing Wisely lists and ACC/AHA chest-pain guidance recommend against routine inpatient stress testing in low-risk patients. Observational studies (including large Medicare analyses) show inpatient stress testing in low-risk chest pain rarely changes management, adds length of stay and cost, and generates downstream angiography without mortality benefit. The 2021 AHA/ACC Chest Pain Guideline favors early discharge with outpatient testing (or no testing) for low-risk patients ruled out by high-sensitivity troponin. Exception: intermediate/high-risk patients or incomplete rule-out still benefit.

Five-score assessment

Consensus 5/5
ACC/AHA chest pain guideline, ACC/AHA perioperative guideline, and SHM/ACP Choosing Wisely all recommend against routine inpatient stress testing in low-risk patients.
Evidence certainty 3/5
Evidence base is mostly observational cohorts and guideline consensus rather than large RCTs comparing inpatient vs no-test strategies.
Replication 4/5
Safavi 2014, Foy 2015, Hermann 2013 and related analyses independently show low yield and wide practice variation without outcome differences.
Contradiction 1/5
Some argue stress testing identifies a small high-risk subset missed by troponin alone, but magnitude is small and not outcome-changing.
Directness 4/5
Outcomes studied include downstream catheterization, revascularization, MI/death, length of stay — directly patient-relevant.

Scope

Population
Hospitalized adults with low pretest probability of CAD (e.g., low-risk chest pain, preoperative low-risk non-cardiac surgery)
Intervention
Inpatient provocative stress testing (exercise ECG, stress echo, nuclear MPI) prior to discharge
Outcome
Downstream invasive procedures, length of stay, MACE, cost
Not supported for
  • High pretest-probability patients with ongoing ischemic symptoms
  • Acute coronary syndrome workup where rule-out is incomplete
  • Patients with abnormal biomarkers or ECG changes

Evidence sources

Supporting (4)

Account mentions